Celyad Oncology S.A.
CYAD · NASDAQ
12/31/2024 | 6/30/2024 | 12/31/2023 | 6/30/2023 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | – | $6 | $7 | $5 |
| Short-Term Investments | – | $0 | $0 | $0 |
| Receivables | – | $0 | $3 | $1 |
| Inventory | – | $0 | $1 | $0 |
| Other Curr. Assets | – | $2 | $4 | $2 |
| Total Curr. Assets | – | $9 | $11 | $8 |
| Property Plant & Equip (Net) | – | $2 | $2 | $1 |
| Goodwill | – | $0 | $0 | $0 |
| Intangibles | – | $0 | $0 | $1 |
| Long-Term Investments | – | $2 | $3 | $3 |
| Tax Assets | – | $0 | -$2 | -$3 |
| Other NC Assets | – | $0 | $3 | $3 |
| Total NC Assets | – | $4 | $5 | $4 |
| Other Assets | – | $0 | $0 | $0 |
| Total Assets | – | $13 | $16 | $12 |
| Liabilities | – | – | – | – |
| Payables | – | $1 | $1 | $3 |
| Short-Term Debt | – | $0 | $0 | $0 |
| Tax Payable | – | $0 | $0 | $0 |
| Deferred Revenue | – | $0 | $1 | $1 |
| Other Curr. Liab. | – | $1 | $2 | $2 |
| Total Curr. Liab. | – | $2 | $3 | $6 |
| LT Debt | – | $1 | $1 | $0 |
| Deferred Rev, NC | – | $0 | $0 | $4 |
| Deferred Tax Liab, NC | – | $0 | $0 | $0 |
| Other NC Liab. | – | $6 | $6 | $0 |
| Total NC Liab. | – | $7 | $7 | $5 |
| Other Liabilities | – | $0 | $0 | $0 |
| Cap. Leases | – | $1 | $1 | $1 |
| Total Liabilities | – | $10 | $10 | $11 |
| Equity | – | – | – | – |
| Pref Stock | – | $0 | $0 | $0 |
| Common Stock | – | $8 | $33 | $79 |
| Retained Earnings | – | -$361 | -$358 | -$354 |
| AOCI | – | $356 | $332 | $270 |
| Other Equity | – | $0 | $0 | $6 |
| Total Equity | – | $3 | $6 | $1 |
| Supplemental Information | – | – | – | – |
| Minority Interest | – | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | – | $13 | $16 | $12 |
| Net Debt | $0 | -$5 | -$6 | -$4 |